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The sodium (Na)-calcium (Ca2) exchanger 1 (NCX1) is an
important regulator of intracellular Ca2 homeostasis. Serine
68-phosphorylated phospholemman (pSer-68-PLM) inhibits
NCX1 activity. In the context of Na/K-ATPase (NKA) regu-
lation, pSer-68-PLM is dephosphorylated by protein phospha-
tase 1 (PP1). PP1 also associates with NCX1; however, the
molecular basis of this association is unknown. In this study, we
aimed to analyze themechanisms of PP1 targeting to theNCX1-
pSer-68-PLM complex and hypothesized that a direct and func-
tional NCX1-PP1 interaction is a prerequisite for pSer-68-PLM
dephosphorylation. Using a variety of molecular techniques, we
show that PP1 catalytic subunit (PP1c) co-localized, co-frac-
tionated, and co-immunoprecipitated with NCX1 in rat car-
diomyocytes, left ventricle lysates, and HEK293 cells. Bioinfor-
matic analysis, immunoprecipitations, mutagenesis, pulldown
experiments, and peptide arrays constrained PP1c anchoring to
the K(I/V)FF motif in the first Ca2 binding domain (CBD) 1 in
NCX1. This binding site is also partially in agreement with the
extended PP1-binding motif K(V/I)FF-X5–812-X8–9-R.
The cytosolic loop of NCX1, containing the K(I/V)FF motif,
had no effect on PP1 activity in an in vitro assay. Dephosphor-
ylation of pSer-68-PLM in HEK293 cells was not observed
when NCX1 was absent, when the K(I/V)FF motif was
mutated, or when the PLM- and PP1c-binding sites were sep-
arated (mimicking calpain cleavage of NCX1). Co-expression
of PLM and NCX1 inhibited NCX1 current (both modes).
Moreover, co-expression of PLM with NCX1(F407P) (mu-
tated K(I/V)FF motif) resulted in the current being com-
pletely abolished. In conclusion, NCX1 is a substrate-speci-
fying PP1c regulator protein, indirectly regulating NCX1
activity through pSer-68-PLM dephosphorylation.
The sodium (Na)-calcium (Ca2) exchanger (NCX)3 is a
bidirectional ion-transporting membrane protein, which
exchanges three Na for one Ca2 across the plasma mem-
brane. Its mode of operation and activity are determined by the
ion concentration gradients and membrane potential (1). In
mammals, there are three distinct genes that control the
expression of three NCX isoforms (NCX1, NCX2, and NCX3)
that are expressed in a tissue-specific manner (2, 3). Among
these, NCX1 is highly expressed in cardiomyocytes, where it
modulates excitation-contraction coupling and mediates Ca2
removal during diastole (4). Increased NCX1 mRNA and pro-
tein levels have been shown in human end-stage heart failure
(HF) (5–7), and elevated activity of NCX1 has been linked to
dysfunctional Ca2 handling in chronic heart disease (8). Con-
sequently, modulation of NCX1 activity constitutes a potential
therapeutic target in the treatment of HF (9).
NCX1 cDNA encodes a protein of 973 amino acids in
humans, which includes a 32-amino acid signaling peptide that
is cleaved during processing (10). The eukaryotic exchanger is
composed of 10 transmembrane domains (TM) (11, 12), with a
large cytosolic loop between TM5 and TM6. Deletion of the
cytosolic loop has revealed that it does not play a direct role in
ion translocation, but rather it mediates regulation of the
exchanger by associatingwith various cytosolic factors (13–16).
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NCX1 has been shown to exist in amacromolecular complex
comprising protein kinase A (PKA) and C (PKC), protein phos-
phatase 1 (PP1) and 2A (PP2A), as well as other anchoring and
adaptor proteins (17). Direct regulation of NCX1 by kinases is
controversial (18); in fact, we have shown that there is no phos-
phorylation of endogenous NCX1 following PKA activation,
and we concluded that the identified phosphorylation site was
not accessible in full-length NCX1 (19). It has been suggested
that phosphorylation and dephosphorylation rather occur on
accessory proteins in theNCX1macromolecular complex, ena-
bling fine-tuning of signals that converge on NCX1 (17). Accu-
mulating data indicate that PLM is one of these regulatory play-
ers. This 72-amino acid transmembrane protein, belonging to
the FXYD1 family of ion transporters (20), co-localizes and co-
immunoprecipitates with NCX1 and has been shown to inhibit
NCX1 activity when it is phosphorylated at serine 68 (pSer-68-
PLM) (21–24). Interestingly, pSer-68-PLM relieves inhibition
of the Na/K-ATPase (NKA), causing an increase in NKA
activity (25, 26), suggesting that PLMmay serve as a regulator of
bothNCX (24) andNKA (27) depending on its phosphorylation
status. pSer-68-PLM is in turn regulated by PP1 (28). The latter
is a ubiquitously expressed 38.5-kDa serine/threonine phos-
phatase that counters the effects of serine/threonine kinases
and has little intrinsic specificity for its substrates (29). Mam-
malian genomes encode four distinct catalytic subunits of PP1
as follows: PP1, PP1/, and the splice variants PP1c1 and
PP1c2 (30). The isoforms show 85% sequence identity, but the
N- and C-terminal extremities show amino acid differences
(30). The catalytic subunit (PP1c) achieves substrate specificity
by forming holoenzymeswithmore than 200 targeting proteins
(31). These targeting proteins localize PP1c to specific subcel-
lular domains and fine-tune its activity, allowing for substrate-
specific effects (31). More than 90% of targeting proteins inter-
act with PP1c via a short degenerate RVXF-docking motif (32),
which serves as an anchor for the initial recruitment of PP1c.
Although dephosphorylation of pSer-68-PLM, by PP1c, was
recently shown to modulate pSer-68-PLM regulation of NKA
(28), it is unknown whether this mechanism is involved in
NCX1 regulation.
In this study, we investigated whether a direct and functional
NCX1-PP1c interaction is a prerequisite for pSer-68-PLM de-
phosphorylation. Bioinformatic and biomolecular approacheswere
used to investigate this hypothesis.We aimed tomap the PP1c-
targeting site on the NCX1 macromolecular complex and elu-
cidate the biological effect of this interaction on NCX1 activity.
Experimental Procedures
Animal Model—Animal experiments were approved by the
Norwegian Animal Research Committee (FOTS ID 3820) and
conformed to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publication No. 85-23,
revised 1996). Male Wistar rats (Møllergaard Breeding and
Research Center, Skensved, Denmark) weighing 170 g were
subjected to aortic banding, as described previously (33, 34).
In short, anesthesia was induced in a chamber containing a
mixture of 68%N2O, 28%O2, and 4% isoflurane. After endotra-
cheal intubation, ventilation was performed with a respirator
(Zoovent, Triumph Technical Services, Milton Keynes, UK),
and anesthesia was maintained by administration of a mixture
of 69% N2O, 29% O2, and 2% isoflurane. The chest was opened
in the right second intercostal space, and the ascending aorta
was carefully dissected. A significant stenosis was induced by a
tight banding of the ascending aorta with a 3.0 silk suture. In
sham-operated animals (SHAM), the silk suture around the
ascending aorta was not tightened. Buprenorphine was admin-
istered for postoperative analgesia. After 6 weeks, echocardiog-
raphy was performed with a Vevo 2100 (Fujifilm VisualSonics,
Canada), and short and long axis images of the left ventricle
(LV) and atrium were obtained. The flow through the mitral
and aortic valve was measured. Aortic banding animals with
congestive heart failure (ABHF) were selected based on echo-
cardiographic, hemodynamic, and post-mortem analysis. The
criteria for inclusion in the ABHF group were increased poste-
rior wall diameter (1.9 mm), increased LV weight (0.75 g),
increased lung weight (2.5 g), and increased left atrial diame-
ter (5.0mm) (34). The SHAMgroup served as control. All LV
samples were snap-frozen in liquid nitrogen and stored at
70 °C until analysis.
Isolation of Neonatal Cardiomyocytes—Neonatal rat car-
diomyocytes were isolated from 1- to 3-day-old Wistar rats.
The LV was enzymatically digested in a collagenase solution.
The cell mix was transferred onto uncoated culture flasks and
incubated for 20 min. Unattached cardiomyocytes were seeded
onto 6-well culture plates coated with 0.2% gelatin (G1890,
Sigma) and 0.1% fibronectin (F1141, Sigma). The seeding den-
sity was 3.75  105 cells/ml in Dulbecco’s modified Eagle’s
medium-high glucose (DMEM) (D1152, Sigma) supplemented
with Medium 199 (M2520, Sigma), penicillin/streptomycin
(P0781, Sigma), horse serum (14-403E, BioWhittaker,Walkers-
ville, MD), and fetal bovine serum (FBS) (14-701F, BioWhit-
taker). The cultures weremaintained in a humidified incubator
with 5%CO2 at 37 °C for 24 h until used in protein fractionation
experiments.
Adult Cardiomyocyte Isolation—Rats were anesthetized in a
chamber filled with 95% room air and 5% isoflurane (Abbott
Scandinavia Ab, Solna, Sweden) and were subsequently sacri-
ficed by cervical dislocation. Hearts were then quickly excised
and placed in ice-cold 0.15 MNaCl solution with heparin (Hep-
arin LEO, 5000 IE/ml; Orifarm AS, Norway). The aorta was
then cannulated and retrogradely perfused with a cell isolation
buffer containing 130 mM NaCl, 25 mM Hepes, 22 mM D-glu-
cose, 5.4 mM KCl, 0.5 mMMgCl2, 0.4 mM NaH2PO4, pH 7.4 (all
chemicals from Sigma) to wash out the blood. The heart was
thereafter perfused with cell isolation buffer containing 200
units/ml collagenase type II (Worthington) and 0.1 mM Ca2.
After 20min of perfusion, the heart was cut down, and the atria
and right ventricle were removed. The LV was minced and
gently shaken at 37 °C for 3–4min in the same solution used in
the perfusion, but with addition of 1% bovine serum albumin
(BSA) (A9647, Sigma) and 0.02 units/ml deoxyribonuclease I
(LS002006, Worthington). The digested ventricular tissue was
then filtered (200-m nylon mesh), and cardiomyocytes were
sedimented. The cardiomyocyte pellet was resuspended in cell
isolation buffer with 1% BSA (A9647, Sigma) and 0.1 mM Ca2
in the solution. Isolated cardiomyocytes were kept at room
temperature until used.
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Antibodies—The primary antibodies used are as follows:
anti-NCX1 (custom-made, epitope: GQPVFRKVHARDHPI-
PST, Genscript Corp., Piscataway, NJ) (19); anti-rabbit IgG (sc-
2027, Santa Cruz Biotechnology, Santa Cruz, CA); anti-PP1
(E-9) (sc-7482, Santa Cruz Biotechnology); anti-mouse IgG (sc-
2025, Santa Cruz Biotechnology); anti-FXYD1 (total PLM)
(ab76597, Abcam plc, Cambridge, UK); anti-vinculin (V9131,
Sigma); anti-His6 (A00186, Genscript Corp.); anti-serine 68 phos-
phorylated phospholemman (pSer-68-PLM) (35); anti-GFP
(632381, Clontech); anti-DYKDDDDK (FLAG tag) (A00170-
40, Genscript Corp.); anti-FLAGM2 (F3165, Sigma); anti-bi-
otin horseradish peroxidase (HRP) (A0185, Sigma); anti-His6
HRP (against a polyhistidine (His6 tag) epitope) (R931-25, Life
Technologies, Inc.); anti-GST HRP (RPN 1236V, GE Health-
care, Little Chalfont, Buckinghamshire, UK), and anti-calse-
questrin (PA1-913, Thermo Fisher Scientific, Waltham,
MA). The secondary antibodies used are as follows: anti-
rabbit IgG HRP (NA934V, GE Healthcare); anti-mouse IgG
HRP (NA931V, GE Healthcare); anti-goat IgG HRP
(HAF109, R&D Systems, Bio-Techne, Minneapolis, MN);
anti-sheep IgG HRP (6150-05, Southern Biotech, Birming-
ham, AL); and anti-mouse IgG HRP, light chain-specific
(115-005-174, Jackson ImmunoResearch).
Bioinformatic Analyses—Human, mouse, and rat NCX1 pro-
tein sequences (P32418, O35157, and Q01728) as well as hu-
manandratPLMsequences (O00168andO08589)were screened in
silico for putative PP1-binding motifs, (RK)X0–1(VI)X(FW), as
defined by Wakula et al. (32). Using the Protein Pattern Find-
Bioinformatics.org database, the consensus sequence input was
as follows in the program, [RK].{0,1}[VI].[FW]. NCX1 se-
quenceswere also screened for the presence of the12 and/or
arginine motifs, as defined by Choy et al. (36). Lasergene (DNA
Star, Madison, WI) was used for protein alignments.
Total Protein Extracts—Frozen rat LV lysates were pulver-
ized in a mortar with liquid nitrogen before transfer to lysis
buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
TritonTM X-100 (X100–500ML, Sigma)) supplemented with 1
mM PMSF (93482, Sigma) and a Complete Mini EDTA-free
tablet (11836170001, Roche Diagnostics, Basel, Switzerland).
Tissue samples were homogenized three times for 1 min on ice
with a Polytron 1200 and centrifuged at 100,000 g for 60 min
at 4 °C. Supernatants were collected and stored at70 °C until
analysis.
Fractionation—LVs from rat heart and neonatal cardiomyo-
cyte cultures were fractionated using the compartment protein
extraction kit according to the manufacturer’s protocol (2145,
Merck Millipore Billerica, MA). The supernatants from cyto-
solic and/or membrane fractions were collected and stored at
70 °C. Protein concentrations, where applicable, was deter-
mined by the Micro BCA protein assay kit (23235, Thermo
Fisher Scientific).
DNAConstructs—Cloning andmutations of NCX1, PP1, and
PLM constructs were performed by Genscript Corp. The pri-
mary sequence numbering in all NCX variants includes the sig-
nal peptide sequence. The MGC mouse clone BC079673 was
used for NCX1 constructs. WT NCX1 full-length (FL) was
cloned into pEGFP-N1 (Clontech) or into the first reading
frame of pAdTrack-cytomegalovirus (CMV) shuttle vector
(plasmid 16405, Addgene, Cambridge, MA). Ala mutants
(I406A and F408A or K405A and F407A) were mutated into
NCX1/pEGFP-N1. A Pro substitution mutant (F407P) was
cloned into NCX1/pEGFP-N1. Deletion mutants of the cyto-
plasmic loop of NCX1, NCX1(243–787), NCX1(243–705),
NCX1(243–532), NCX1(243–402), and NCX1(399–424),
were cloned into pEGFP-C2 (Clontech). The rat catalytic sub-
unit (P62138) was used for PP1 constructs, and an N-terminal
FLAG and His6 tag were inserted. FLAG-His6-PP1c(1–330)
and deletion mutants FLAG-His6-PP1c(1–212), FLAG-His6-
PP1c(1–149), and FLAG-His6-PP1c(232–263) were cloned
into pCEP4 vector (Invitrogen). Single and double glycine
mutants of FLAG-His6-PP1c (L243G,F257G) were mutated
into pCEP4 (Invitrogen). Mouse PLM (AF089734) was cloned
into pcDNA3.1/Myc-HisA (Invitrogen) by Genscript Corp.
The fidelity of the cloning procedure and mutagenesis were
verified by sequence analysis (GenscriptCorp.). The empty vec-
tors pcDNA3.1 and pEGFP-N1 were obtained from Invitrogen
and Clontech, respectively. Tobacco etch virus (TEV) protease
in pCS2MT was kindly provided by Prof. Pati (37).
Transient Transfection of HEK293 Cells—Human embryonic
kidney 293 (HEK293) cells were cultured in DMEM (41965-
039, Gibco, Life Technologies, Inc.) supplemented with 10%
FBS (14-701F, BioWhittaker), 1% non-essential amino acids
(10370-021, Gibco, Life Technologies, Inc.), 100 units/ml pen-
icillin, and 0.1 mg/ml streptomycin (penicillin/streptomycin,
P4333, Sigma) and maintained in a 37 °C, 5% CO2-humidified
incubator. Cells were cultured in medium without antibiotics
24 h prior to transfection. Cells were transfected with DNA
using Lipofectamine 2000, as instructed by the manufacturer
(11668-019, Invitrogen), or a solution containing CaCl2. For
this method, two solutions were prepared: solution A (124 mM
CaCl2 and 8 g of plasmid DNA diluted in 500 l of purified
water) and solutionB (50mMHEPES, 280mMNaCl, and 1.5mM
Na2HPO4 in 500 l of PBS, pH 7.0). The two solutions were
thenmixed together and incubated at room temperature for 30
min. After the 30 min, HEK293 cells were incubated with the
mixed solution for 18–24 h (38). After 24 h, the cells were either
transferred to coverslips forpatchclamp/Ca2-dependent fluo-
rescence experiments or lysed in immunoprecipitation (IP)-
buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5%
TritonTM X-100) supplemented with a Complete Mini EDTA-
free tablet (11836170001, Roche Diagnostics) and used in
molecular studies. In thepatch clamp/Ca2-dependent fluores-
cence experiments, the glass coverslips were pre-coated with
poly-L-lysine (P4707, Sigma), and the cells on the coverslips
were incubated for 24 h prior to analysis. GFP was used as a
positive control for the transfection.
Peptide Synthesis—Peptides were purified to80% purity by
Genscript Corp. anti-NCX1-blocking peptide (amino acids
655–672), (C)-GQPVFRKVHARDHPIPST;biotin-NCX1(KVFF)
(amino acids 399–424, rat), ENDPVSKVFFEQGTYQCLENC-
GTVAL; biotin-NCX1 (KAFA) mutant, ENDPVSKAFAEQG-
TYQCLENCGTVAL; biotin-NCX1 (AVAF) mutant, ENDPV-
SAVAFEQGTYQCLENCGTVAL; biotin-NCX2 (amino acids
389–410, rat), EDDGASRIFFEPSLYHCLENCG; and biotin-
NCX3 (amino acids 392–412, rat), EDFASKVFFDPCS-
YQCLENCG.
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Recombinant Proteins—The recombinant proteins usedwere
as follows: PP1 (14–595, Merck Millipore Billerica); custom-
made His6-trigger factor (TF)-NCX1cyt and GST-PP1 (both
Genscript Corp.); PP1 (P0754S, New England Biolabs, Ips-
wich,MA); and PP1 inhibitor 2 (P0755S,NewEngland Biolabs).
Spot Membrane Synthesis—The cytosolic loop (amino acids
243–799) of rat NCX1 protein (EDM02743) and rat PP1 catalytic
subunit (P62138) (PP1c)were synthesizedas20-merpeptideswith
a three-amino acid overlap on cellulose membranes using a Mul-
tipep automated peptide synthesizer (INTAVIS Bioanalytical
InstrumentsAG,Cologne,Germany), asdescribedpreviously (39).
Overlay Assay—Peptide array membranes, consisting of
either theNCX1or PP1c sequence, were activated by soaking in
methanol for a few seconds and followed by threewashes (three
times for 10 min) with TBS-T (Tris-buffered saline with 1%
Tween 20 (161-0781, Bio-Rad)). The membranes were then
incubated with blocking solution (1% casein) (11921673001,
Roche Diagnostics) at room temperature for 1 h. Next, the
membranes were either overlaid with 1 g/ml recombinant
His6-TF-NCX1cyt or 1 g/ml GST-PP1 recombinant protein
(in 1% casein) overnight at 4 °Cwith gentle agitation. Themem-
branes were then washed five times for 5 min with TBS-T and
incubated with anti-His6 HRP or anti-GST HRP-conjugated
antibody for 1 h at room temperature. The bound protein on
the membranes was detected by immunodetection. Incubation
of the membranes without recombinant protein was used as a
negative control. For antibody epitope mapping, incubation of
the membranes without primary antibody was used as a nega-
tive control.
Pulldown Experiments—Biotinylated peptides (10 mM) were
incubated with 25 l of anti-biotin-conjugated beads (A1559,
Sigma) and 100 l of PBS for 2 h at 4 °C under gentle rotation.
The beads with bound peptides were then washed three times
with PBS followed by incubation with 1 g of GST-PP1
recombinant protein in 100 ml of IP-buffer supplemented with
1% BSA (805095, Bio-Rad) followed by gentle rotation for 2 h at
4 °C. The peptide complex was washed three times with 1ml of
IP-buffer. To elute the complex, it was boiled in 2 SDS loading
buffer and analyzed by immunoblotting.
Immunoprecipitation (IP)—IP was performed using 2 g of
the appropriate antibody. The immunocomplexes were col-
lected by 50 l of protein A/G PLUS-agarose beads (sc-2003,
Santa Cruz Biotechnology) overnight at 4 °C. They were then
washed three times with 1 ml of IP-buffer followed by the
boiling of the complexes in 2 SDS loading buffer. Analysis
was done by immunoblotting. Equal amounts of rabbit IgG (sc-
2027, Santa Cruz Biotechnology) and mouse IgG (sc-2025,
Santa Cruz Biotechnology) were used as negative controls.
Blocking peptide (antigen, cardiac NCX1; sequence, (C)-
GQPVFRKVHARDHPIPST) (Genscript Corp.) was incubated
with anti-NCX1 prior to immunoprecipitation (negative
control).
Proximity Ligation Assay (Duolink)—Isolated adult rat car-
diomyocytes were plated on laminin (23017-015, Life Technol-
ogies, Inc.)-coated glass coverslips and left to adhere for 1 h.
The cells were fixed in 4% paraformaldehyde (158127, Sigma),
permeabilized with 0.03% Triton X-100 (X100–500ML,
Sigma), and incubated with the two primary antibodies anti-
NCX1 (rabbit polyclonal antibody) and anti-PP1c (mouse
monoclonal antibody) overnight at 4 °C. Staining without pri-
mary antibodies and use of an anti-NCX1 blocking peptide was
used as a negative control. The proximity ligation assay was
performed using the Duolink kit (DUO92014, Sigma) accord-
ing to themanufacturer’s protocol, as described previously (15).
The cells were then incubated with 600 nM SYTOX Orange
(S-11368, Life Technologies, Inc.), a nucleic acid stain, for 10
min at room temperature and rinsed three times for 5min with
PBS. Imaging experiments were performed at 25 °C. Thewater-
based Duolink In Situ Mounting Medium (refractive index
1.44), provided in the kit, was used to mount the glass coverslip
to the glass slide. The fluorochromes usedwere theDuolink In
Situ Detection Reagents Green (excitation 488 nm and emis-
sion 510 nm) and SYTOXOrange (excitation 543 nmand emis-
sion 650 nm). The cells were visualized with an inverted LSM
710 confocal microscope (Zeiss GmbH, Jena, Germany)
equipped with an LDC-Apochromat40 objective (numerical
aperture 1.1). Sequential optical scans were acquired using the
Zeiss ZEN imaging software.
Immunoblotting—LV lysates and immunoprecipitates were
resolved on either 4–15% or 15%CriterionTMTris-HCl precast
gels (Bio-Rad) and blotted onto PVDF membranes (RPN 303F,
GE Healthcare). The PVDF membranes and peptide arrays
were blocked in 5% nonfat dry milk or 1% casein in TBS-T for
60 min at room temperature, followed by incubation with
primary antibodies either for 1 h at room temperature or over-
night at 4 °C. The membranes were washed three to five times
for 5 min in TBS-T and incubated with a horseradish peroxi-
dase-conjugated secondary antibody. Blots were developed
using ECL Plus or Prime (RPN 2132 or RPN 2232, GE Health-
care). The chemiluminescence signals were detected by Las-
4000 (Fujifilm, Tokyo, Japan).Membraneswere re-probed after
stripping using the Restore Western blot Stripping buffer
(21059, Thermo Scientific).
Protein Phosphatase 1 Activity Assay—Phosphatase activity
was measured in vitro by a nonradioactive assay using a mala-
chite green-based phosphatase assay kit (40) (17-128, Merck
Millipore), according to the manufacturer’s protocol. Briefly, 1
unit of PP1 recombinant protein (P0754S, New England Bio-
labs) was incubated with 200M (RRApSVA) peptide substrate
together with either a range of His6-TF-NCX1cyt recombinant
protein concentrations or biotinylated NCX1 peptides in a
phosphatase buffer (50 mM HEPES, 10 mM NaCl, 2 mM DTT,
0.01% Brij 35, pH 7.5) supplemented with 1 mM MnCl2 for 20
min at 37 °C. Next, 100 ml of malachite green dye was added to
the solution and incubated for 15 min at room temperature. A
spectrophotometer, absorbance set at 650nm,was used tomea-
sure the colored complex formed upon the release of free phos-
phate. The amount of released phosphate was calculated using
a standard curve created with various concentrations of
KH2PO4. PP1 inhibitor 2 was used as a control for the assay.
Protein Kinase A (PKA) Phosphorylation Assay—PKA assays
were performed using cAMP-dependent protein kinase, cata-
lytic subunit (PKA-C) (P6000S, New England Biolabs) as
instructed by the manufacturer. PKA-C and 1 NEBuffer for
protein kinases (P6000S, New England Biolabs), supplemented
with 200 M ATP, were added to the HEK293 cell lysates, fol-
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lowed by incubation for 30 min at 30 °C. PKA-C treatment was
omitted for control samples. Kinase reaction was stopped by
adding sample buffer. The samples were subsequently sub-
jected to SDS-PAGE and immunoblotting.
Patch Clamp Studies—Whole cell patch clamp experiments
were conducted on HEK293 cells transfected with WT
NCX1(FL), WT NCX1(FL) co-transfected with PLM or Pro
substitution mutant NCX1(F407P) co-transfected with PLM
using anAxoclamp 200B amplifier (Axon Instruments) and low
resistance pipettes (2–4 megaohms). We also determined the
current of the NCX1(F407P) mutant alone, as a control for the
experiment. The recordings were performed at 37 °C in an
extracellular solution containing (in mM) the following: 140
NaCl, 5 CsCl, 1.2MgSO4, 1.2 NaH2PO4, 5 CaCl2, 10 HEPES, 10
glucose, pH 7.4 (CsOH), and osmolality at 290mOsm. To block
K, Ca2, Cl, and NKA currents, we used cesium, nifedipine
(20 M), niflumic acid (30 M), and ouabain (1 mM), respec-
tively. The patch pipettes were filled with a solution composed
of (in mM) the following: 100 cesium glutamate, 4 NaCl, 1
MgCl2, 10 HEPES, 2 Na2-ATP, 10 EGTA, 6 CaCl2, pH 7.2, and
osmolality 270mOsm. Free intracellular Ca2was 369 nM. Liq-
uid junction potential was calculated using pCLAMP 10 soft-
ware (Molecular Devices) and corrected by 15 mV (Vmembrane	
Vpipette  (15 millivolts (mV))). The NCX1 reversal potential
under these conditions was 40 mV at 37 °C. Cells were volt-
age-clamped at 40 mV for 4–5 min to allow sufficient intra-
cellular dialysis. NCX1 current was elicited by a descending
voltage ramp from 120 to 100 mV (0.05 V/s) and isolated
using 5 M Ni2. The currents were normalized to cell capaci-
tance and the current (I)-voltage (V) relations were plotted
from80 to 80 mV.
Measurement of Intracellular Ca2—Cytosolic Ca2 con-
centrations were determined from HEK293 cells transfected
withWTNCX1(FL), WTNCX1(FL) co-transfected with PLM,
or Pro substitution mutant NCX1(F407P) co-transfected with
PLM. Cells were seeded and transfected on poly-L-lysine-
coated coverslips 48 h prior to the experiment. On the day of
the experiment, transfectedHEK293 cells were preincubated in
Tyrode’s solution (140mMNaCl, 5mMHEPES, 5.4mMKCl, 0.5
mM MgCl2, 5.5 mM D()-glucose monohydrate, 0.4 mM
NaH2PO4, 1.8 mMCaCl2, 1M ouabain, and 1M thapsigargin,
37 °C). The cells were then loaded with 5 M fluo-4 acetoxy-
methyl ester (F14202, Molecular Probes-Thermo Fisher) for
10 min at room temperature, mounted in a superfusion cham-
ber on a Zeiss LSM510 confocal microscope (Zeiss Gmbh, Jena
Germany), and visualized with a W Plan-Apochromat 40
objective (numerical aperture 	 1.0, Zeiss). Fluorescence was
excited by a 480 nm light-emitting diode (Colibri lamp, Zeiss),
and emission was collected at515 nmwith a photomultiplier
tube (R1527P, Horiba Scientific, Edison, NJ). Ca2-dependent
fluorescence was monitored as the superfusing solution was
changed from the initial Tyrode’s solution ([Na]	 140mM) to
aNa-free solution (140mMcholine chloride, 5mMHEPES, 5.4
mMKCl, 0.5mMMgCl2, 5.5mMD()-glucosemonohydrate, 1.8
mM CaCl2, 1 M ouabain, and 1 M thapsigargin, 37 °C), to
induce Ca2 influx via reverse-mode NCX1. Data acquisition
and analysis were performed with Clampex 10.4 and Clampfit
10.4 software, respectively (Molecular Devices LLC, Sunnyvale,
CA). Ca2 recordings were background-subtracted and are
presented normalized to baseline fluorescence (F/F0).
SPR Analysis—SPR analysis was performed using BIAcore
X100. A desorb step in IP-buffer supplemented with 1% BSA
was performed before each analysis. Recombinant His6-TF-
NCX1cyt (ligand) in acetate, pH 4.0, was immobilized on CM5
chips using N-hydroxysuccinimide and 1-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide. His6-TF-NCX1cyt was immobi-
lized in three independent experiments to 189, 419, and 443
resonance units. Recombinant GST-PP1 (analyte) was diluted
over a range of concentrations (31.3–500, 6.25–100, and
9.8–50 nM) in the buffer above and injected over the sensor
surface at a flow rate of 30 l/min for 180 s. The dissociation
time was 600 s at the same flow rate. Obtained sensorgrams
were analyzed by BIAcore X100 evaluation software.
Structure Modeling—Atomic coordinates for human PP1 in
complex with the PP1 and PDZ domains of rat spinophilin
(PDB code 3EGG (41)) were used to build amodel of the NCX1
tetrapeptide 405KVFF408 binding to PP1. The peptide was built
by homology modeling using the 448KIHF451 segment of the
spinophilin as a template. The side chain conformations of the
middle Val and Phe residues were selected based on the orien-
tation of the corresponding Ile and His residues in spinophilin,
respectively. The structural models of the complexes were ana-
lyzed and visualized by PyMOL (Schrodinger LLC).
Densitometric Analysis—Densitometric analysis was per-
formed using ImageJ (National Institutes of Health), and blots
were processed in Adobe Photoshop CS2 (Adobe Systems Inc.,
San Jose, CA).
Statistics—All data were expressed as mean
 S.E. relative to
control. Comparisons between two groups were analyzed using
the unpaired t test or Mann-Whitney test (GraphPad software,
Prism 5.04). A p value of 0.05 was considered statistically
significant.
Results
Bioinformatic Analysis to Identify PP1-binding Sites in
NCX1—The Protein Pattern Find-Bioinformatics.org database
was used to search for putative PP1-binding motifs in NCX1
and PLM, with the consensus sequence (R/K)(V/I)X(F/W) (see
under “Experimental Procedures” for details). No PP1-binding
sites were found in PLM; however, three putative binding sites
were identified in human, mouse, and rat NCX1. The first site,
RVFF, is localized within the cytosolic loop connecting TM3
and -4. The second site, KIFF/KVFF (human andmouse/rat), is
localized in the large cytosolic loop in the first Ca2 binding
domain (CBD1), the primary sensor of calcium (42). The KIFF/
KVFF site does not overlap with the sites in CBD1 that coordi-
nate the fourCa2 ions (43). The third site, KVLF, is localized at
the end of the intracellular loop (Fig. 1).
PP1 Binds Directly to NCX1—Several experiments were per-
formed to show that PP1 interacts with NCX1. First, immuno-
detection with specific antibodies for NCX1 (as published pre-
viously (19)) and PP1 (Fig. 2A, antibody epitope mapping)
showed that a pool of PP1 catalytic subunit (PP1c) is localized
with NCX1 in membrane fractions isolated from rat LV (Fig.
2B, left panels) and neonatal cardiomyocytes (Fig. 2B, right pan-
els). Second, immunoprecipitation of NCX1 in LV lysate and
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immunoblotting with antibodies against PP1c and PLM identi-
fied a NCX1-PLM-PP1c macromolecular complex (Fig. 2C).
Third, using the proximity ligation assay, we showed that
NCX1 and PP1c co-localize in isolated adult rat cardiomyo-
cytes, strongly indicating that NCX1 and PP1c are in the same
molecular complex (as indicated by the green fluorescent spots
in Fig. 2D, 1st panel). No signal was observed when primary
antibodieswere omitted (Fig. 2D, 2ndpanel) orwhen theNCX1
antibody was pre-incubated with a specific anti-NCX1-block-
ing peptide (Fig. 2D, 3rd panel). Fourth, immunoprecipitation
of recombinant His6-TF-NCX1cyt (Fig. 2E, schematic figure)
using His6 or NCX1 antibodies showed that recombinant PP1
precipitated with His6-TF-NCX1cyt (Fig. 2F), suggesting NCX1
andPP1 to be direct binding partners. Fifth, the binding kinet-
ics of the GST-PP1-NCX1 interaction was analyzed by SPR.
A range of concentrations of recombinant GST-PP1 was
injected over immobilized recombinant His6-TF-NCX1cyt on a
CM5 chip and analyzed with the fit of a 1:1 interaction model
(Langmuir). The dissociation equilibrium constant (KD) for the
interaction was 3.02 
 1.48 nM, with an association rate con-
stant (ka)	 (6.10
 3.35) 104 M1 s1 and a dissociation rate
constant (kd) 	 (1.71 
 0.95)  104 s1 (Fig. 2G). Conclu-
sively, SPR data indicated that the GST-PP1-NCX1 interac-
tion was strong and stable.
PP1 Anchors to the KIFF/KVFF Motif in NCX1-CBD1—To
identify PP1 binding in NCX1, mouse NCX1(FL)-GFP and a
series of GFP-NCX1 deletion mutants were expressed in
HEK293 cells (Fig. 3A, schematic figure). Fishingwith anti-PP1c
and recombinant GST-PP1 in the HEK293 lysates and immu-
noblotting with anti-GFP revealed that all NCX1 variants pre-
cipitated, except for GFP-NCX1(243–402) (Fig. 3B), whichwas
lacking CBD1 containing the KIFF/KVFF motif. The bottom
panel shows expression of the NCX1 variants and GFP (nega-
tive control) inHEK293 lysates (Fig. 3B). Tomap the PP1-bind-
ing site more precisely, the cytosolic loop of rat NCX1 was
synthesized as 20-mer overlapping peptides on a membrane
and incubated with recombinant GST-PP1, followed by anti-
GST HRP incubation and immunodetection. Interestingly,
GST-PP1 bound to 399ENDPVSKVFFEQGTYQCLENCGT-
VALTII427 containing the KVFF motif (Fig. 3C, boxed se-
quence). Notably, some GST-PP1 binding was also observed
to amino acids C-terminal to the KVFF motif (408FEQGTYQ-
CLENCGTVALTII427) (Fig. 3C, underlined amino acids).
Introducing Gly sequentially to the C terminus showed that
GST-PP1 bindingwas lostwhen the asparagine (Asn-418)was
deleted (Fig. 3D), suggesting additional amino acid-binding
sites C-terminal to the KVFF motif to be a requisite for PP1
binding. Noteworthy, no GST-PP1 binding was observed for
theKVLF-containing sequence, which has previously been sug-
gested to be a putative PP1-binding site (Fig. 3C, upper panel,
lower box) (17).
Several mutation strategies were employed to test the effect
of PP1 binding to the KIFF/KVFF mouse/rat, motif. Ala substi-
tution at the second and fourth position in the KIFF/KVFF
motif (KAFA mutant) has been shown to be an effective muta-
tion strategy, as it disrupts PP1 binding (44–46). However,
upon examination of the Ca2-bound CBD1 crystal structure
of dog NCX1 (PDB code 2FWS), we noted that the Ile and Phe
in the second and fourth position, localized in the -1 strand in
-sheet 1, seem to be buried in the CBD1 structure. Thus, it
seemed more sensible to mutate the Lys, at the first position,
and Phe, at the third position (AIAF mutant), as these are the
accessible residues. We also generated a Pro substitution
mutant (F407P), and in a fourth construct the KIFF motif was
deleted (GFP-NCX1(399–424)). All variants were expressed
in HEK293 cells and immunoprecipitated with anti-NCX1.
PP1c co-precipitated with NCX1(FL)-GFP but not with GFP-
NCX1(I406A,F408A) (Fig. 4A), GFP-NCX1(K405A,F407A)
(Fig. 4B), GFP-NCX1(F407P) or the deletion, GFP-NCX1-
(399–424) (Fig. 4C). Interestingly,more PP1c co-precipitated
with NCX1 in the presence of 3 mM CaCl2 (Fig. 4D). In a final
experiment, the rat peptide sequence 402PVSKVFFEQGTYQ-
CLENCGT421 (identified in Fig. 3C) and corresponding se-
quences with KVFF substituted for KAFA or AVAF were over-
laid with GST-PP1. Strong binding was observed for the
native peptide, but not to the KAFA or AVAF mutations (Fig.
4E). Altogether, the data supports that PP1 anchors to the
KIFF/KVFF motif in NCX1.
NCX1-KIFF/KVFF Is an Independent, Non-regulatory PP1c-
anchoring Site—To confirm NCX1-KIFF/KVFF as an indepen-
dent PP1c-binding site, we generated biotinylated NCX1-
KVFF, NCX1-KAFA, and NCX1-AVAF peptides (Fig. 5A,
schematic figure). Pulldown experiments using anti-biotin-cou-
pled agarose beads showed that GST-PP1 precipitated with
biotin-NCX1-KVFF but not biotin-NCX1-KAFA (Fig. 5B) or
biotin-NCX1-AVAF (data not shown).When the NCX1-KVFF
peptide orHis6-TF-NCX1cyt recombinant proteinwas tested in
an in vitro PP1 activity assay, no change in recombinant PP1
activity was observed (Fig. 5, C and D, respectively), indicating
that the NCX1-KIFF/KVFFmotif is a non-regulatory PP1c-an-
choring site. Sequence alignments show that the NCX1-KIFF/
KVFF PP1c-anchoring site is highly conserved across human,
rat, and mouse NCX1 (Fig. 5E) and that NCX2 and NCX3 har-
bor RIFF and KVFF motifs, respectively (Fig. 5F). Therefore,
FIGURE 1. Putative PP1-binding motifs within NCX1. Topology model of
Na/Ca2 exchanger 1 (NCX1) consisting of 10 transmembrane domains
(TMs) and a large cytosolic loop between TM5 and TM6 (11, 12) is shown.
Within the TMs are two  repeats (1 and 2) that face opposite sides of the
membrane and catalyze ion translocation (36) (TMs involved in ion transloca-
tion are shown in black). The cytosolic loop mediates regulation of the
exchanger and contains the two Ca2-binding domains (CBD1 and CBD2). In
silico screening of human, rat, andmouseNCX1primary sequences identified
three putative PP1-binding motifs. The first site, RVFF, is localized within the
membrane loop connecting TM3 and -4. The second site, KIFF/KVFF (human
andmouse/rat), is localized inCBD1, and the third site, KVLF, is localized at the
end of the intracellular loop.
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FIGURE 2. PP1c binds directly to NCX1. A, epitope mapping was performed by overlaying an array of immobilized overlapping 20-mer rat PP1- (P62138)
peptides with anti-PP1 (E-9) (sc-7482, top panel). Amino acids in bold constitute the core epitope, localized in the PP1 catalytic subunit (PP1c), and are relevant
for anti-PP1c binding (n 	 2). Immunodetection without anti-PP1c was used as a negative control (bottom panel). B, NCX1 and PP1c were analyzed in
cytoplasmic andmembrane fractions isolated from rat LV and neonatal cardiomyocytes using anti-NCX1 and anti-PP1c (in triplicate). Vinculin and epidermal
growth factor receptor (EGFR) were used as controls for cytoplasmic and membrane fractions, respectively. C, rat LV lysates were subjected to immunopre-
cipitation (IP) using anti-NCX1 (in triplicate). Immunoprecipitates (right panels) and lysate (input; positive control for the immunoblot, left panels) were
immunoblotted with NCX1, PP1c, and PLM antibodies. As a negative control, NCX1 antibody pre-incubated with a specific anti-NCX1 blocking peptide or
non-relevant rabbit IgGwas used.D, confocal images of in situproximity ligation assay. NCX1-PP1c co-localizationwas analyzed in adult cardiomyocytes using
anti-NCX1 and anti-PP1c (left panel, interaction indicated by green spots, see “Experimental Procedures” for details). Incubation without primary antibodies
(middle panel) and pre-incubating anti-NCX1 with blocking peptide (right panel) were used as negative controls. Nuclei were stained with SYTOX orange. E,
schematic figure of recombinant proteins used in this study. The cytosolic loop of NCX1was purified, and His6 and trigger factor (TF) tags were added to the N
terminus (His6-TF-NCX1cyt, top panel). Because of the size of the tags, His6-TF-NCX1cyt migrates as a 150-kDa protein. Commercially available PP1was used in
the initial analysis of the interaction (in F) after which rat PP1- (P62138) with a GST tag (GST-PP1) was generated (bottom panel) and used in the remainder
of the study. F, recombinant proteins were subjected to immunoprecipitation using anti-NCX1 and anti-His6 (in triplicates). Immunoprecipitates (right panels)
andproteins (input panels; positive control for the immunoblot)were immunoblottedwith anti-NCX1 and anti-PP1c. As a negative control, non-relevant rabbit
and mouse IgG were used. G, SPR analysis was performed by immobilizing recombinant His6-TF-NCX1cyt (ligand) on a CM5 chip andmeasuring the response
when injecting a range of concentrations of GST-PP1 (analyte) (n	 3).
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biotinylatedNCX isoformpeptides (schematically illustrated in
Fig. 5A) were also generated and used in pulldown experiments.
Using equal amounts of peptides, we found strong GST-PP1c
binding to biotin-NCX1(399–424), some binding to biotin-
NCX3(392–412), andweak binding to biotin-NCX2(389–410)
(Fig. 5G).
PP1c Dephosphorylates pSer-68-PLM and Regulates NCX1
Activity through NCX1-KIFF/KVFF Anchoring—First, exis-
tence of the NCX1-PLM-PP1c macromolecular complex was
confirmed in lysates from HEK293 cells co-transfected with
NCX1(FL)-GFP and PLMand immunoblotting with antibodies
against NCX1, PP1c, and PLM (Fig. 6A). Second, to determine
whether NCX1 anchoring is required for dephosphorylation of
pSer-68-PLM by PP1c, FLAG-His6-PP1c(1–330) and PLM
were expressed with and without NCX1(FL)-GFP in HEK293.
PLM has been reported to be 30–40% phosphorylated by
endogenous kinases in HEK293 (24, 47), and immunodetection
with a specific anti-pSer-68-PLM (Fig. 6B, antibody epitope
mapping) showed that PLM was highly phosphorylated in
HEK293 (Fig. 6C, lanes 4–6, anti-pSer-68-PLM level). Impor-
tantly, the pSer-68-PLM/total PLM level was significantly
decreased in PLM FLAG-His6-PP1cNCX1(FL)-GFP com-
pared with PLM  FLAG-His6-PP1c (0.4 
 0.03 versus 1.0 

0.05). This suggests that NCX1 anchoring is a prerequisite for
dephosphorylation of pSer-68-PLM by PP1c (Fig. 6C, lanes
7–9). Consistently, when the KIFF/KVFF motif was mutated
FIGURE 3.Mapping of the PP1c interaction site in NCX1. A, schematic figure showing full-length NCX1-GFP and a series of GFP-NCX1 deletionmutants that
were generated to map the PP1c interaction site in NCX1. The numbering of NCX1 includes the N-terminal amino acid signal peptide sequence. B, GST-PP1
together with NCX1 deletion variants were subjected to immunoprecipitation (IP) using anti-PP1c (in triplicates). Precipitates were analyzed with immuno-
blotting. The asterisks in the top panel indicate the NCX1 dimer (64) and missing GFP-NCX1(243–402) fragment. Noteworthy, the GFP-NCX1(243–402) frag-
ment was not visible when we re-ran the samples on a second gel with good separation around 50 kDa and used a light chain-specific antibody (data not
shown). The middle panel shows anti-PP1c-precipitated GST-PP1. In the bottom panel the input lysates were immunoblotted to show the migration and
corresponding molecular weight of NCX1-GFP and the deletion mutants. The asterisks in this panel indicate the NCX1 dimer, monomer, andmigration of the
GFP-NCX1(243–402) deletion fragment. C, identification of PP1 binding by overlaying GST-PP1 on 20-mer overlapping NCX1 peptides synthesized on
membrane. Rat NCX1 protein (EDM02743) was used spanning amino acids 243–799. Binding was analyzed using anti-GST HRP (n	 2) top panel. Boxed areas
show KVFF and KVLF respectively. Underlined amino acids in the first boxed area represent the RVXF -PP1-binding motif and a putative12 motif, whereas
amino acids in bold indicate the common sequence in the four peptide sequences. Incubationwithout GST-PP1was used as a negative control (lower panel).
D, one of the peptide sequences identified in C; 402PVSKVFFEQGTYQCLENCGT421, was synthesizedwith a glycine spacer andwas overlaidwith GST-PP1 (right
panel) to determine the effect on PP1 bindingwhen EN, putative12motif, was deleted (n	 2). The peptide sequencewithout GST-PP1 served as negative
control (left panel).
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(GFP-NCX1(F407P)) or deleted (GFP-NCX1(399–424)), PP1c
was not able to dephosphorylate pSer-68-PLM, as shown by a
significant increase of pSer-68-PLM/total PLM level in PLM
FLAG-His6-PP1c  GFP-NCX1(F407P) (2.4 
 0.04 versus
1.0 
 0.09) and a significant increase of pSer-68-PLM/total
PLM level in PLM  FLAG-His6-PP1c  GFP-NCX1(399–
424) (2.0 
 0.10 versus 1.0 
 0.09) compared with PLM 
FLAG-His6-PP1cNCX1(FL)-GFP (Fig. 6D, lanes 4–9 versus
lane 1–3).
To exclude that the presence of NCX1 prevents PLM phos-
phorylation, lysate fromFLAG-His6-PP1c(1–330) andPLMco-
expressed with or without NCX1(FL)-GFP was treated with or
without active PKA-C.Our results indicated thatNCX1 did not
block the pSer-68-PLM phosphorylation, as the increase in the
pSer-68-PLM/total PLM level was similar between the two
groups (Fig. 6E).
Finally, the biological role of endogenous PP1c on NCX1
activity through dephosphorylation of PLM was analyzed in
HEK293 cells. First, the whole cell patch clamp technique was
employed. NCX1 current was isolated by measuring Ni2-sen-
sitive current elicited during a slow voltage ramp from 120 to
100mV. Co-expression of PLMwithWTNCX1(FL) resulted
in NCX1 inhibition (both forward and reverse mode), consis-
tentwithwhatwas reported previously (Fig. 7F) (PLM is endog-
enously phosphorylated 30–40% by kinases in HEK293) (22).
Moreover, mutation of the PP1c-anchoring site in NCX1
(NCX1(F407P)) resulted in more NCX1 inhibition (Fig. 7F),
indicating that endogenous PP1c was not able to dephosphor-
ylate the pool of phosphorylated PLM.Noteworthy, the current
of NCX1(F407P) alone was similar to that of WT NCX1(FL)
(Fig. 7E). Current traces of the various transfections are given in
Fig. 7, A–D.
NCX1 function was further examined by measuring Ca2-
dependent fluorescence in transfected HEK293 cells. Extracel-
lular Na concentration was rapidly changed from 140 to 0mM
to induce Ca2 entry via reverse-mode NCX1 activity. In
accordance with observations in the patch clamp experiments,
NCX1-mediated Ca2 influx observed in WT NCX1-trans-
fected cells wasmarkedly reducedwhen PLMwas co-expressed
with WT NCX1(FL) (F/F0 	 1.6 
 0.08 versus 1.9 
 0.18).
Mutation of the PP1c-anchoring site in NCX1 (NCX1(F407P))
resulted in a further decrease in the intracellular calcium level
FIGURE 4. Confirmation of the PP1c interaction site in NCX1 by mutagenesis. NCX1(FL)-GFP, containing the KIFF motif (mouse sequence), together
with either GFP-NCX1(I406A, F408A) representing KAFA mutant (A), GFP-NCX1(K405A, F407A) representing the AIAF mutant (B), or GFP-NCX1(F407P)
representing the proline substitution KIPF and GFP-NCX1(399–424) representing KIFF deletion (C) were generated and expressed in HEK293 cells after
which they were used in immunoprecipitation (IP) experiments. The NCX1 antibody was used to precipitate NCX1 followed by immunoblotting with
anti-PP1c for determination of PP1 association.D, rat LV lysates were subjected to immunoprecipitation using anti-NCX1, with and without the addition
of 3 mM CaCl2. Immunoprecipitates (right panels) and lysate (input panels, positive controls for the immunoblot) were immunoblotted using relevant
antibodies. E, peptide sequence 402PVSKVFFEQGTYQCLENCGT421 (identified in Fig. 3C) with KVFF motif was mutated to KAFA and AVAF and overlaid
with GST-PP1 to determine the effect of mutations (n	 2). GST-PP1 binding was analyzed by immunodetection with anti-GST HRP. All experiments
were run in triplicates (A–D).
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when co-expressed with PLM (F/F0	 1.2
 0.05) (Fig. 8). Alto-
gether, our data strongly suggest that NCX1-associated PP1c
dephosphorylates pSer-68-PLM.
Mapping of the NCX1 Interaction Site in PP1c—To deter-
mine the reciprocal NCX1-binding site in PP1, PP1c with an
N-terminal FLAG and His6 tags, along with two deletion
mutants, were generated and expressed in HEK293 cells (Fig.
9A, schematic figure). Immunoprecipitation experiments using
His6-TF-NCX1cyt together with the PP1c deletion variants
revealed that His6-TF-NCX1cyt precipitated only with FLAG-
His-PP1c(1–330) but not with the deletions (Fig. 9B). To map
NCX1 binding in PP1c more precisely, 20-mer overlapping
peptides of rat PP1c were synthesized onmembranes that were
overlaid with recombinant His6-TF-NCX1cyt. The residues
forming the RVXF binding pocket are dispersed in the PP1 pri-
mary sequence (Fig. 9E, denotedwith stars). Nevertheless, weak
NCX1 binding was observed for the peptide sequence 235FLH-
KHDLDLICRAHQVVEDGYEFFAK260, containing Asp-242,
Leu-243, and Phe-257 (Fig. 9C, boxed sequences). These
amino acids form part of the RVXF binding pocket (30).
FIGURE 5. Independence and isoform specificity of the NCX1-KIFF/KVFF-anchoring site. A, schematic figure of NCX1-biotinylated peptides used in
pulldown and PP1 activity assays. B, pulldown assaywith the biotinylated NCX1 peptides andGST-PP1 recombinant protein (in triplicates). PP1 binding
was analyzed by immunoblotting with anti-PP1c (upper panel). Anti-biotin HRP was used to show the presence of biotinylated peptides. Incubation of
the GST-PP1 recombinant protein with only the beads was used as negative control. C, effect of NCX1-PP1 interaction on PP1 activity was assessed. In
each experiment, 1 unit of active PP1c was incubated with a range of recombinant His6-TF-NCX1cyt protein concentrations or (D) biotinylated NCX1
peptides for 20min, after which the activity was determined. Inhibitor 2 (PP1 inhibitor) was used as control for the assay. The KIFF/KVFF-anchoringmotif,
a putative12 motif (EN) and a conserved argininemotif (R), are shown in the alignment of human, rat, mouse NCX1 (E) and NCX1–3 isoforms (F) (black
boxes indicate similar functional amino acids (DNA Star). G, pulldown assay with the biotinylated NCX1–3 peptides and GST-PP1 recombinant protein
(in triplicates). PP1 binding was analyzed by immunoblotting with anti-PP1c (upper panel). Incubation of GST-PP1 recombinant protein with only the
beads was used a negative control. GST-PP1 recombinant protein and biotinylated NCX peptides were used as positive controls for the immunoblot
in B and G (input panels on left).
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FIGURE6.Analysisof theNCX1,PP1c, andPLMmacromolecular complex inHEK293cells.A,HEK293cellswere co-transfectedwithPLMandNCX1(FL)-GFP.
The lysates were subjected to immunoprecipitation (IP) using anti-NCX1. Immunoprecipitates (right panels) and lysate (input; positive control for the immu-
noblot, left panel) were immunoblotted with NCX1, PP1c, and PLM antibodies. As a negative control NCX1 antibody pre-incubated with a specific anti-NCX1
blocking peptide or non-relevant rabbit IgG was used. B, epitope mapping was performed by overlaying an array of immobilized overlapping 20-mer PLM
peptides with anti-pSer-68-PLM (right panel) (n	 2) (35). Immunodetection without anti-pSer-68-PLM was used as a negative control (left panel). FLAG-His6-
PP1c(1–330) and PLM were expressed with and without either NCX(FL)-GFP (C) or GFP-NCX1(F407P) (D), representing the proline substitution KIPF, or
GFP-NCX1(399–424), representing KIFF deletion, inHEK293 followedby immunoblottingwith anti-NCX1, FLAG, pSer-68-PLM, and total PLM.Non-transfected
HEK293 cells were used as control in C. Bar graph shows relative pSer-68-PLM/total PLM level quantified by densitometry analysis. Differences were tested using
unpaired t test (**, p 0.01; ***, p 0.001). E, lysate fromFLAG-His6-PP1c(1–330) and PLM co-expressedwith orwithout NCX1(FL)-GFP in HEK293were treatedwith
orwithout active PKA-C, followed by immunoblottingwith anti-pSer-68-PLM and total PLM. Bar graph shows the relative pSer-68-PLM/total PLM level quantified by
densitometry analysis. Differenceswere tested using unpaired t test (ns.; not significant). All experimentswere performed in triplicates (A–E).
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Interestingly, Phe-257 is reported as an important anchoring
site in PP1c (48). To validate this interaction site, a deletion
mutant, FLAG-His6-PP1c(232–263), without the putative
interaction site, was generated and expressed in HEK293
cells. Lysates were incubated with recombinant His6-TF-
NCX1cyt. Immunoprecipitation with anti-FLAG showed loss
of interaction with FLAG-His6-PP1c(232–263) deletion,
suggesting that the constrained binding region is important
for NCX1 binding (Fig. 9D).
Structural Modeling of NCX1-KVFF into PP1—A homology
model was generated of the rat NCX1 tetrapeptide 405KVFF408,
binding to rat/human PP1c using the 448KIHF451 PP1c binding
segment of rat spinophilin (PDB code 3EGG) as template (Fig.
10A). It shows that Val-406 may fit into a hydrophobic pocket
formed by Ile-169, Leu-243, and Leu-289 in PP1c and that Phe-
407 may interact with Met-290. The peptide backbone forms
hydrogen bonds with Asp-242, Leu-289, and Cys-291. Phe-257
andArg-261 also play an important role in peptide binding. The
conformation of the KVFF motif in this model is essentially
similar to the conformation of the homologous KIFF motif as
found in the NMR and x-ray structures of the Canis Lupus
NCX1 ((PDB code 2FWS) (42) and (PDB code 2DPK (49)), the
only difference being the orientation of the Lys side chain.
However, large rearrangements in the NCX1 must take place
upon binding to PP1c in order for the motif to be accessible for
binding. To further test the model, Leu-243 and Phe-257 were
single and double-mutated to Gly as follows: FLAG-His6-PP1c
(L243G), FLAG-His6-PP1c (F275G), andFLAG-His6-PP1c (L243G,
F275G). Immunoprecipitation showed that FLAG-His6-
PP1c(1–330) co-precipitatedHis6-TF-NCX1cyt, but no binding
was observed for the PP1c mutants (Fig. 10B). This lends sup-
port to Leu-243 and Phe-257 in PP1c being important residues
for NCX1 anchoring.
pSer-68-PLM-NCX1-PP1c Complex Is Increased in HF—To
analyze the pSer-68-PLM-NCX1-PP1c levels in failing hearts,
membrane fractions were isolated from SHAM and ABHF rats.
FIGURE 7.Whole cell patch clamp analysis of NCX1 regulation by PLM and PP1c. HEK293 cells were transfected with WT NCX1(FL), WT NCX1(FL), and
PLM or Pro substitution mutant NCX1(F407P) and PLM. NCX1 current was elicited by a descending voltage ramp from 120 to100 mV. Current traces
of WT NCX1(FL) (n 	 9) (A), NCX1(F407P) (n 	 7) (B), WT NCX1(FL) and PLM (n 	 6) (C), and NCX1(F407P) and PLM (n 	 5) (D) are shown. E and F,
relationship between current (normalized to cell capacitance) and membrane voltage (Vm), presented for potentials between80 and80 mV. *, p
0.05 (WT NCX1(FL) PLM versusWTNCX1(FL) and NCX1(F407P) PLM versusWTNCX1(FL)). #, p 0.05 (NCX1(F407P) PLM versusWTNCX1(FL) PLM
(n 	 5)).
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Animal characteristics are listed in Table 1. Immunoblotting
showed that the PP1c/calsequestrin level was significantly
increased in ABHF hearts compared with SHAM (1.9 
 0.10
versus 1.0
 0.03). The pSer-68-PLM/total PLM level was also
significantly increased in ABHF hearts compared with SHAM
(1.3 
 0.10 versus 1.0 
 0.03) (Fig. 11A). We have previously
shown that the NCX1 level is up-regulated in response to pres-
sure overload in our animal model (15), similar to what others
have shown (5, 50). Anti-calsequestrin and anti-total PLMwere
used as controls. Recently, we have identified a calpain cleavage
site at Met-369 in NCX1, which resides between the PLM-an-
choring site (16) and PP1c-anchoring site (this study).
Wanichawan et al. (15) showed that calpain activity was greatly
increased in ABHF hearts and that this correlated with
increased cleavage ofNCX1. To test whether calpain cleavage is
responsible for dissociating PP1c away from PLM, HEK293
cells were co-transfected with PLM, FLAG-His6-PP1c(1–330),
and NCX1(TEV). In NCX1(TEV), the calpain cleavage site is
engineered into a TEV protease site. Interestingly, the pSer-68-
PLM/total PLM level was significantly increased in PLM 
FLAG-His6-PP1c  NCX1 (TEV)  TEV/pCS2MT (HEK293
cells co-transfected with the enzyme that cleaves the TEV
sequence) compared with PLM  FLAG-His6-PP1c 
NCX1(TEV) (HEK293 cells are not co-transfected with the
enzyme) (1.3 
 0.08 versus 1.0 
 0.05) (Fig. 11B), indicating
that calpain cleavage of NCX1 at Met-369 separates the PLM-
and PP1c-anchoring sites. A model of PP1c anchored onto
NCX1-KIFF/KVFF leading to dephosphorylation of pSer-68-
PLM is summarized in Fig. 12, A and B (effect of calpain
cleavage).
Discussion
In an ongoing effort to understand regulation of cardiac
NCX1 activity, we have investigated the molecular basis
of PP1c targeting to the NCX1 macromolecular complex,
and we determined the functional consequences of this
interaction.
PP1c Anchors to the NCX1-KIFF/KVFFMotif in CBD1—PP1
targeting is predominantly mediated by a short RVXF-docking
motif, which is present in 90% of targeting proteins (31, 51).
Therefore, bioinformatic analysis was used to search for RVXF
motifs on PLM and NCX1. No RVXF motifs were identified in
PLM, but three putative RVXFmotifs were identified in NCX1,
two of which were localized to the cytosolic loop, which medi-
ates NCX1 regulation.
Several experiments were conducted, which suggest that the
KVFFmotif in the rat NCX1 cytosolic loop (KIFF in human and
mouse NCX1) is the PP1c-targeting site responsible for pSer-
68-PLMdephosphorylation. 1) PP1c bounddirectly to the cyto-
solic loop of recombinantNCX1. 2) Peptide array data localized
PP1c binding to NCX1-KVFF. Binding to other putative
PP1c-binding motifs was not observed. 3) PP1c binding was
abolished when the KVFF motif was deleted or mutated to
KAFA or AVAF, both in the NCX1 full-length protein and in
20-mer NCX1 peptides. 4) Presence of NCX1 was a pre-
requisite for dephosphorylation of pSer-68-PLM by PP1c.
No dephosphorylation was observed when the NCX1 full-
length protein was absent or when the KVFF motif was
mutated. 5) The NCX1 cytosolic loop, containing KVFF, had
no effect on PP1 activity, confirming an anchoring role of
NCX1. 6) Finally, the electrophysiological experiments dem-
onstrated that mutation of the PP1c KVFF site suppresses
NCX1 activity and that this suppression is mediated through
an increased pSer-68-PLM level.
As mentioned above, loss of the NCX1-PP1c interaction was
observed with both the NCX1-KAFA and NCX1-AVAF muta-
tions.We also generated a proline substitutionmutant, NCX1-
(F407P), and the obtained results are in agreement with studies
reporting that proline is not tolerated at position X in RVXF
FIGURE 8.NCX regulationbyPLMandPP1c analyzedbyCa2-dependent fluorescence.Ca2 entry intoHEK293 cells via reverse-modeNCX1 functionwas
induced by rapidly decreasing extracellular [Na].A, representative recordings of Ca2 fluorescence fromHEK293 cells transfectedwithWTNCX1(FL) (n	 11),
or NCX1(FL) and PLM (n 	 11), or NCX1(F407P) and PLM (n 	 6). B, bar graph shows Ca2 recordings that were background-subtracted and are presented
normalized to baseline fluorescence (F/F0) level quantified by Clampex 10.4 and Clampfit 10.4 software, respectively. Differences were tested using unpaired
t test: *, p 0.05 (WT NCX1(FL) PLM versusWT NCX1-(FL)). **, p 0.005 (NCX1(F407P) PLM versusWT NCX1(FL)). #, p 0.05 (NCX1(F407P) PLM versus
WT NCX1(FL) PLM)).
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because it prevents -strand formation (31). Other proteins
that adopt a more rigid structure upon PP1-binding are spi-
nophilin andMYPT1. Spinophilin forms a-strand upon bind-
ing to PP1, which extends a -strand structure in PP1 (52).
Although regulator proteins adopt a distinct conformation
when bound to PP1, they do not significantly change the PP1
structure.
It has been suggested that most PP1-targeting proteins com-
binemultiple dockingmotifs to form a stable complexwith PP1
(53). Thus, in addition to looking for the RVXF motifs, we
scanned the NCX1 primary sequence for additional PP1-dock-
ing motifs. NCX1 was found to partially fulfill the extended
PP1-binding motif, RVXF-X5–812-X8–9-R (36). By intro-
ducing glycine mutations to the C terminus of KVFF in the
array, loss of binding was observed with N418G, suggesting
Asn-418 to be part of the 12 motif. Using the JackHMMER
(54), Peti et al. (30) constrained2 to amino acids FIYRHNQSC
and 1 to amino acids VIYFH. Thus, Glu-417 does not fit into
FIGURE 9.Mapping of the NCX1 interaction site in PP1. A, schematic figure showing PP1c and two deletion mutants that were generated to map the
NCX1 interaction site in PP1. A FLAG and His6 tags were inserted on the N terminus. The arrow indicates NCX1 binding region. B, His6-TF-NCX1cyt
together with the PP1 deletion variants were subjected to immunoprecipitation using anti-FLAG (in triplicates). Precipitates were analyzed with
immunoblotting. C, identification of NCX1 binding by overlaying His6-TF-NCX1cyt on 20-mer overlapping rat PP1 (P62138) peptides synthesized on
membrane. Binding was analyzed using anti-His6 HRP (n 	 2). Boxed area shows His6-TF-NCX1cyt binding to PP1c; amino acids in bold indicate the
common sequence in the three peptide sequences, and underlined amino acids form part of the RVXF binding pocket. D, FLAG-His6-PP1c(1–330)
together with a variant, where the NCX1 binding region was deleted; FLAG-His6-PP1c(232–263) was used in immunoprecipitation experiments. The
anti-FLAG antibody was used to precipitate FLAG-His6-PP1c variants expressed in HEK293 cells followed by immunoblotting with anti-NCX1 for
determination of NCX1 association with PP1c (in triplicates). His6-TF-NCX1cyt in lysate from non-transfected HEK293 cells was used as a negative control.
E, residues that are important for PP1-binding of target proteins (30) is shown by the stars in the alignment of human,mouse, and rat PP1. The boxed area
show His6-TF-NCX1cyt binding to PP1 (identified in C).
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the pure 1 definition; however, the 12 motif is considered
to be variable. Additionally, there is a conserved Arg-428 in
NCX1. Therefore, in addition to the RVXF PP1-binding motif,
the partial 12 motif and the conserved Arg-428 on NCX1
may form part of a high affinity PP1-binding site. The Arg
motif in the PP1 nuclear targeting subunit (PNUTS)-PP1
holoenzyme has been shown to work as a substrate selectiv-
ity filter, by blocking access to the C-terminal binding groove
(36). Therefore, dephosphorylation of pSer-68-PLMmay not
require binding to the C-terminal groove, and PP1 interac-
tion sites such as SILK (55) and MyPhoNE (56) were not
found in NCX1. Several PP1 holoenzyme complexes have
been reported to be regulated by phosphorylation of amino
acids flanking the RVXF motifs (31). NCX1 possesses both a
serine and threonine close to the KIFF/KVFF motif, suggest-
ing that PP1 targeting to NCX1 might be dynamic. Scan-
site.mit.edu software identified the flanking phosphoryla-
tion sites in NCX-KIFF/KVFF as putative casein kinase or
Src kinase phosphorylation sites.
NCX1 Binds to the Hydrophobic Pocket in PP1c—PP1c dele-
tion mutants constrained NCX1 binding to amino acids 212–
330 in the N terminus of PP1c. Consistently, the peptide array
assay showed very weak binding to the sequence 235FLHKH-
DLDLICRAHQVVEDGYEFFAK260. The Asp-242, Leu-243,
and Phe-257 residues are localized in -sheets 10 and 11 and
form part of the RVXF binding pocket, where Asp-242 exhibits
a high excess of negative charges, and Leu-243 and Phe-257
form part of the hydrophobic pocket (30, 57). These different
properties of the PP1 surface determine the amino acid types
tolerated at the different ligand positions. To confirm that
NCX1 anchoring to PP1 is mediated by the residues in the
hydrophobic pocket, we generated glycine single and double
mutations of FLAG-His6-PP1c (L243G and F257G). Our
peptide docking model, with the NCX-KVFFmotif in human
NCX1 based on the PP1-spinophilin complex, shows that
NCX1-Val-406may fit onto a hydrophobic pocket formed by
Ile-169, Leu-243, and Leu-289 in PP1. Furthermore, the
NCX1-Phe-407 may interact with PP1-Met-290. The con-
formation of the KVFF motif in this model is similar to the
conformation of the homologous KIFF motif, as found in the
NMR and x-ray structures of the Canis Lupus NCX1 (Protein
Data Bank code 2FWS (42) and Protein Data Bank code
2DPK (49)).
The PP1-NCX1 interaction was strong (Kd of 3.0 nM), in a
similar range to that of PNUTS-PP1// (9.3 nM) (36) and
FIGURE 10.Model of NCX1-KVFF peptide binding to PP1. A, homologymodel of rat NCX1 peptidemotif KVFF binding to human/rat PP1. The KVFF peptide
(green stick model) interacts with PP1 (light blue surface and stick model of selected residues) via polar hydrogen bonds (black dashed lines) and hydrophobic
contacts (red dashed lines). The directions of extension of the peptide are indicated by two black arrows. B, PP1c (FLAG-His6-PP1c(1–330)) together with
FLAG-His6-PP1c single and double mutants (L243G, F257G) were immunoprecipitated with anti-FLAG, followed by immunoblotting with anti-NCX1 to deter-
mine co-precipitation of recombinant His6-TF-NCX1cyt (in triplicates).
TABLE 1
Animal characteristics of rats showing SHAM controls and ABHF
The following abbreviations are used: LV, left ventricle; BW, body weight; RV, right
ventricle; IVSd, interventricular septum in diastole; PWd, posteriorwall thickness in
diastole; LVDd/s, left ventricular diameter in diastole or systole, respectively; FS,
fractional shortening; LAD, left atrial diameter; HR, heart rate; CO, cardiac output;
LVOT, left ventricular outlet tract.
SHAM ABHF
Organ weights
Number (n) 9 5
BW (g) 364
 6 353
 12
Heart weight (g) 1.01
 0.05 2.31
 0.19a
LV weight (g) 0.66
 0.03 1.23
 0.04a
LV/BW ratio (mg/g) 1.8
 0.1 3.5
 0.2a
RV weight (g) 0.17
 0.01 0.29
 0.02a
Lung weight (g) 1.33
 0.05 3.28
 0.34a
Echocardiography
M-mode
IVSd (mm) 1.6
 0.0 2.2
 0.1a
PWd (mm) 1.6
 0.1 2.0
 0.1a
LVDd (mm) 6.3
 0.2 7.3
 0.3a
LVDs (mm) 3.4
 0.2 4.3
 0.5
FS (%) 55
 5 42
 5a
LAD (mm) 3.5
 0.1 5.5
 0.4a
Doppler
Peak mitral flow (mm/s) 908
 42 1039
 20
Mitral deceleration (mm/s2) 2974
 190 4243
 750
HR (beats/min) 438
 5 390
 19a
CO in LVOT (ml/min) 130
 11 105
 12
Tissue Doppler
Maximal systolic velocity (mm/s) 70
 4 49
 8a
Minimal diastolic velocity (mm/s) 72
 3 54
 5a
a p 0.05 SHAM versus ABHF.
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spinophilin-PP1 (8.7 nM) (41). Two-thirds of all PP1-targeting
proteins have a PP1 interaction domain that is predicted to be
intrinsically disordered. These interaction domains adopt a
defined fold upon binding of PP1. X-ray crystallography and
NMR studies have shown a substantial loss of structural integ-
rity in the Ca2-binding sites of NCX1-CBD1 in the absence of
Ca2, but upon Ca2 binding NCX1-CBD1 is arranged into
antiparallel -strands (58). Interestingly, Ile-406 and Phe-408
in canine NCX1, which are part of the identified NCX1-KIFF/
KVFFmotif, have been suggested to be important for stability of
the protein structure (58). We speculate that the PP1-Asp-242
might form a salt bridge with the NCX1-Lys-408, facilitating
high affinity binding, as shown in our SPR analysis results.
Importantly, NCX1 was able to bind PP1-Phe-257 on the pep-
tide array, which has been shown to be an important anchoring
site in PP1, and mutation of this residue to alanine resulted in
loss of PP1-binding (48).
PP1c Anchored to NCX1-KIFF/KVFF, Dephosphorylates
pSer-68-PLM, and Regulates NCX1 Activity in HEK293—We
confirmed that PLM co-precipitates withNCX1 in lysates from
rat cardiomyocytes and HEK293, as reported previously (22).
Immunoblotting with a specific anti-pSer-68-PLM antibody
showed that PLM was highly phosphorylated in HEK293, con-
sistent with reports that PLM is endogenously phosphorylated
(30–40%) by kinases in HEK293 (24, 47). Noteworthy, both
PLM and non-phosphorylatable PLM bind to NCX1 (22); how-
ever, it is pSer-68-PLMthat exerts an inhibitory effect onNCX1
activity (24). The pSer-68-PLM level was significantly reduced
in the presence of NCX1(FL)-GFP, suggesting that NCX1
anchoring is a prerequisite for dephosphorylation of pSer-68-
PLM by PP1c. Co-expression of PLM with WT NCX1(FL)
reduced the current in both forward and reverse mode. More-
over, NCX1 function was almost completely suppressed when
HEK293 cells were co-transfectedwith PLMandNCX1(F407P)
(mutated PP1-anchoring site). These results suggest that PP1
plays a significant role in relievingNCX1 inhibition, by dephos-
phorylating pSer-68-PLM. Reverse mode NCX1 was also
observed to be inhibited in Ca2 fluorescence measurements.
This result is in agreement with Ahlers et al. (22), who used a
radioactive tracer uptake method in HEK293 cells. They found
FIGURE 11. Analysis of NCX1, PP1c, and PLM in SHAM and ABHF rats. A, PP1c, pSer-68-PLM and PLM levels were analyzed in isolated cardiac membrane
fractions by immunoblotting using relevant antibodies (n 	 5). Anti-calsequestrin and total PLM were used as loading controls. Bar graph show relative
PP1c/calsequestrin level and pSer-68-PLM/total PLM level quantified by densitometry analysis. Differences were tested using unpaired t test (*, p 0.05; ***,
p  0.001). B, FLAG-His6-PP1c(1–330), PLM, and NCX1 (TEV) were expressed with or without TEV protease followed by immunoblotting using relevant
antibodies (in triplicates). Bar graph show relative pSer-68-PLM/total PLM level quantified by densitometry analysis. Differences were tested using unpaired t
test (*, p 0.05).
NCX1-associated PP1c Dephosphorylates pSer-68-PLM
4576 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 9•FEBRUARY 26, 2016
 at G
lasgow
 U
niversity Library on N
ovem
ber 7, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
that co-expressingNCX1 andPLMresulted in 15% reduction of
45Ca2 uptake after cells were exposed to a solution containing
zero Na.
PLM-NCX1-PP1c Macro-molecular Complex in HF—Con-
sistent with previous findings (15), we found an up-regulation
of NCX1 expression in our pressure overload model. However,
evaluation of NCX1 function is complex, as an increase in
NCX1 expression does not imply an increase in NCX1 activity.
Indeed, there have been some models showing a decreased or
unchanged NCX1 activity (9, 59). Regulator proteins of NCX1
might also be altered in HF, which also affects NCX1 activity.
The PLM level may vary in different models of hypertrophy or
HF, as indicated in the study by El-Armouche et al. (28), where
they showed a down-regulation of PLM phosphorylation in
human heart failure. Bossuyt et al. (60) found a reduction in
total PLM expression in HF rabbit myocytes, LV homogenates,
and in human HF but an up-regulation in the pSer-68-PLM.
The existence of different pools of PLM in the heart could
account for the different phosphorylation outcomes for the
NKA-associated and NCX1-associated PLM. Such pools are
known to exist in myocytes (61). Global PP1c activity and
expression is increased in human and experimental HF and is
suggested to be a unique characteristic of HF (62). Mice over-
expressing the catalytic subunit of PP1 to similar levels as
observed in HF had depressed cardiac function, dilated car-
diomyopathy, and premature mortality (63).We found up-reg-
ulation of both PP1c/calsequestrin levels and pSer-68-PLM/
total PLM levels in our pressure overload model, suggesting
that PP1 is not able to dephosphorylate pSer-68-PLM. PLM
interacts with two distinct regions in the intracellular loop of
NCX1 (amino acids 238–270 and 300–328) (16) and inhibits
the activity of exchanger. Recently, we showed that NCX1 was
cleaved by calpain in HF and mapped a calpain cleavage site to
Met-369 in NCX1, which separates the PLM- and PP1c (this
study)-anchoring sites. Cleavage at this site led to a reduction in
NCX1 activity (both forward and reversemode) comparedwith
WT NCX1(FL) (15). Interestingly, cleavage at this site in
HEK293 up-regulated pSer-68-PLM/total PLM levels (Fig. 10B;
this study), suggesting that dephosphorylation of pSer-68-PLM
by PP1c is inhibited. This finding could account for why it is
reported that pSer-68-PLM and PP1c levels are up-regulated
in HF.
In conclusion, NCX1 is a substrate-specifying PP1c-tar-
geting protein. NCX1 also facilitates regulation of its own
activity by mediating dephosphorylation of pSer-68-PLM.
FIGURE 12. Proposed model of indirect regulation of NCX1 by PP1c. A, under normal physiological conditions, pSer-68-PLM (phosphorylation
denoted by a circled P) interacts with the PASKT- and QKHPD-containing sequences in the intracellular loop of NCX1 and inhibits NCX1 activity (14, 16,
23, 24). PP1c anchoring onto NCX1-KIFF/KVFF in CBD1 dephosphorylates pSer-68-PLM, relieving inhibition of the exchanger. B, calpain activity is
increased in ABHF hearts (simulating heart failure), and this correlates with increased cleavage of NCX1 at Met-369 (15). This cleavage hinders dephos-
phorylation of pSer-68-PLM by PP1c because it dissociates PP1c away from pSer-68-PLM. Cleavage of NCX1 at Met-369 down-regulates NCX1 current
(both forward and reverse mode) (15).
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